Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Evgen Pharma ( (GB:TCF) ).
TheraCryf plc announced an upcoming investor webinar to discuss its plans for the Ox-1 addiction and SFX-01 glioblastoma programs, following a recent fundraising. This initiative aims to advance the Orexin-1 antagonist to clinical trial readiness, unlocking potential commercial opportunities. The webinar, hosted by Turner Pope Investments, will feature a presentation and Q&A session, providing insights into the company’s strategic direction and market opportunities.
More about Evgen Pharma
TheraCryf plc is a clinical stage drug development company focusing on oncology and neuropsychiatry. It has a broad pipeline in clinical and preclinical stages for conditions such as glioblastoma, neurodevelopmental disorders, addiction, anxiety, and narcolepsy. The company aims to generate compelling data to reach preclinical or clinical proof of concept and partner with mid-size to large pharmaceutical companies for larger trials and commercialization. TheraCryf collaborates with major universities and hospitals and is listed on AIM in London under the ticker symbol TCF.
YTD Price Performance: -56.73%
Average Trading Volume: 3,706,216
Technical Sentiment Signal: Buy
Current Market Cap: £4.79M
For a thorough assessment of TCF stock, go to TipRanks’ Stock Analysis page.